Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin plus methotrexate versus methotrexate alone for newly diagnosed primary central nervous system lymphoma
ChiCTR1800015137Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of idarubicin and methotrexate in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Overall survival. Started Jan 2018; status: recruiting.
02
Drugs
idarubicinmethotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR1800015137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015137.